三陰乳腺癌的內科治療進展_《華西醫學》

作者：

李永霞 ,  劉磊 , 李平 , 汪娟

四川大學華西醫院腫瘤中心（成都，610041）;

關鍵詞：

三陰乳腺癌內科治療

DOI：

CNKI: 51-1356/R.20120115.1555.039

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

三陰乳腺癌是乳腺癌中一類影響乳腺癌預后的特殊類型，因其臨床及病理特點的特殊性，導致三陰乳腺癌的治療成為世界性的難題。近年來，研究者們對三陰乳腺癌的內科治療進行了一系列的探索，加上三陰乳腺癌特殊靶點的發現以及靶向藥物的發展，希望三陰乳腺癌通過內科治療從而改善預后。現對其內科治療進展進行綜述。

引用本文： 李永霞,劉磊,李平,汪娟. 三陰乳腺癌的內科治療進展. 華西醫學, 2012, 27(1): 141-144. doi: CNKI: 51-1356/R.20120115.1555.039 復制

1.	Conforti R, Bidard FC, Michiels S, et al. Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 “triple negative” breast cancers[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S135.
2.	Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Oncol, 2008, 19(7): 1261-1265.
3.	Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.
4.	周波, 謝菲, 王思源, 等. 紫杉類聯合蒽環類的新輔助化療方案治療三陰乳腺癌的療效及預后[J]. 中國癌癥雜志, 2009, 19(2): 129-132.
5.	Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
6.	Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 203.
7.	Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
8.	Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoiso-merase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat, 2008, 107(69): 214.
9.	Ellis P, Barrett-Lee P, Johnson L, et al. Sequential doce-taxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase Ⅲ, randomized controlled trial[J]. Lancet, 2009,.
10.	Königsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients [J]. Cancer Invest, 2011, 29(2): 180-186.
11.	Kennedy CR, Feng Gao, Julie A. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer[J]. J Surg Res, 2010, 163(1): 52-57.
12.	Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol, 2010, 28(3): 375–379.
13.	Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple-negative breast cancer patients compared to non-triple negative patients[J]. Breast, 2010, 19(3): 246-248.
14.	Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience[J]. Ann Oncol, 2011, 22(4): 848-856.
15.	吳立新, 黃玉霞, 方月蘭, 等. 吉西他濱聯合順鉑二線治療晚期三陰乳腺癌的臨床觀察[J]. 安徽醫藥, 2011, 15(9): 1149-1150.
16.	O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial[J]. J Clin Oncol Meeting Abstracts, 2009, 27(18S): 3.
17.	Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer[J]. Anti-Cancer Drugs, 2007, 18(7): 835-837.
18.	Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009)[J]. J Clin Oncol, 2008, 26(suppl 15): 43.
19.	O’Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatinwith or without cetuximab in patients with metastatic breast cancer (abstract 308)[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S32.
20.	Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and ef?cacy[J]. J Clin Oncol, 2009, 27(15S): 551.
21.	Anthony E, Dragun, MD, Jianmin Pan, et al. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study[J]. Am J Clin Oncol, 2011, 34(3): 231-237.
22.	Freedman GM, Anderson PR, Li Tianyu, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation[J]. Cancer, 2009, 115(5): 946-951.
23.	Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
24.	袁中玉, 王樹森, 高巖, 等. 305例三陰乳腺癌患者的臨床特征及預后因素分析[J]. 癌癥, 2008, 27(6): 561-565.
25.	Rhee J, Oh S, Oh D, et al. Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic signi?cance? [J]. J Clin Oncol, 2007, 25(18S): 21088.
26.	林堅, 胡梅, 齊彭煒, 等. 三陰乳腺癌的臨床病理特征及預后[J]. 中國癌癥雜志, 2010, 20(6): 462-465.
27.	Kowalski PJ, Rubin MA, Kleei CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases[J]. Breast Cancer Res, 2003, 5(6): 217-222.
28.	李治, 帥曉明, 黃韜. MMP-2、MMP-9在乳腺癌轉移中作用的研究[J]. 華西醫學, 2006, 21(1): 43-44.
29.	Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and in creased risk for recurrence in patients with triple-negative breast cancer[J]. Ann Oncol, 2008, 19(4): 669-674.
30.	Tischkowitz M, Brunet JS, Bgin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 134.
31.	(9676): 1681-1692.

1. 　Conforti R, Bidard FC, Michiels S, et al. Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 “triple negative” breast cancers[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S135.
2. 　Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Oncol, 2008, 19(7): 1261-1265.
3. 　Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.
4. 　周波, 謝菲, 王思源, 等. 紫杉類聯合蒽環類的新輔助化療方案治療三陰乳腺癌的療效及預后[J]. 中國癌癥雜志, 2009, 19(2): 129-132.
5. 　Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
6. 　Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 203.
7. 　Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
8. 　Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoiso-merase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat, 2008, 107(69): 214.
9. 　Ellis P, Barrett-Lee P, Johnson L, et al. Sequential doce-taxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase Ⅲ, randomized controlled trial[J]. Lancet, 2009,.
10. 　Königsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients [J]. Cancer Invest, 2011, 29(2): 180-186.
11. 　Kennedy CR, Feng Gao, Julie A. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer[J]. J Surg Res, 2010, 163(1): 52-57.
12. 　Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol, 2010, 28(3): 375–379.
13. 　Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple-negative breast cancer patients compared to non-triple negative patients[J]. Breast, 2010, 19(3): 246-248.
14. 　Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience[J]. Ann Oncol, 2011, 22(4): 848-856.
15. 　吳立新, 黃玉霞, 方月蘭, 等. 吉西他濱聯合順鉑二線治療晚期三陰乳腺癌的臨床觀察[J]. 安徽醫藥, 2011, 15(9): 1149-1150.
16. 　O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial[J]. J Clin Oncol Meeting Abstracts, 2009, 27(18S): 3.
17. 　Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer[J]. Anti-Cancer Drugs, 2007, 18(7): 835-837.
18. 　Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009)[J]. J Clin Oncol, 2008, 26(suppl 15): 43.
19. 　O’Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatinwith or without cetuximab in patients with metastatic breast cancer (abstract 308)[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S32.
20. 　Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and ef?cacy[J]. J Clin Oncol, 2009, 27(15S): 551.
21. 　Anthony E, Dragun, MD, Jianmin Pan, et al. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study[J]. Am J Clin Oncol, 2011, 34(3): 231-237.
22. 　Freedman GM, Anderson PR, Li Tianyu, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation[J]. Cancer, 2009, 115(5): 946-951.
23. 　Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
24. 　袁中玉, 王樹森, 高巖, 等. 305例三陰乳腺癌患者的臨床特征及預后因素分析[J]. 癌癥, 2008, 27(6): 561-565.
25. 　Rhee J, Oh S, Oh D, et al. Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic signi?cance? [J]. J Clin Oncol, 2007, 25(18S): 21088.
26. 　林堅, 胡梅, 齊彭煒, 等. 三陰乳腺癌的臨床病理特征及預后[J]. 中國癌癥雜志, 2010, 20(6): 462-465.
27. 　Kowalski PJ, Rubin MA, Kleei CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases[J]. Breast Cancer Res, 2003, 5(6): 217-222.
28. 　李治, 帥曉明, 黃韜. MMP-2、MMP-9在乳腺癌轉移中作用的研究[J]. 華西醫學, 2006, 21(1): 43-44.
29. 　Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and in creased risk for recurrence in patients with triple-negative breast cancer[J]. Ann Oncol, 2008, 19(4): 669-674.
30. 　Tischkowitz M, Brunet JS, Bgin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 134.
31. (9676): 1681-1692.

《華西醫學》

三陰乳腺癌的內科治療進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

三陰乳腺癌的內科治療進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料